LONDON--(BUSINESS WIRE)--Technavio has announced their latest pipeline analysis report on the polycystic ovary syndrome market. The report includes a detailed analysis of the pipeline molecules under investigation within the defined data collection period to treat polycystic ovary syndrome.
This report by Technavio presents a detailed analysis of the market, including regulatory framework, drug development strategies, recruitment strategies, and key companies that are expected to play an essential role in the growth of the market in the future.
This report is available at a USD 1,000 discount for a limited time only: View market snapshot before purchasing
Polycystic ovary syndrome: Market overview
Polycystic ovary syndrome (PCOS) is a hormonal condition, which occurs when a woman’s ovaries or adrenal glands produce more male hormones than normal. PCOS is a common heterogeneous endocrine disorder characterized by irregular menses, hyperandrogenism, and polycystic ovaries. It develops cysts (fluid filled sacs) on the ovaries. It is also known as Stein-Leventhal syndrome. It is one of the most common hormonal endocrine disorders. PCOS is linked to the development of other medical conditions such as insulin resistance, type 2 diabetes, high cholesterol, high blood pressure, and heart disease.
According to a senior market research analyst at Technavio, “Polycystic ovary syndrome is the most common cause of female infertility, affecting 6% to 12% of the US women of reproductive age. PCOS is a lifelong health condition that continues far beyond the child-bearing years.”
Polycystic ovary syndrome: Segmentation analysis
This pipeline analysis report segments the polycystic ovary syndrome market based on therapies employed (monotherapy, combination therapy, and monotherapy/combination therapy), RoA (oral), therapeutic modality (small molecule, and biological), targets (kisspeptin receptor, AMPK, neurokinin 3 receptor, and others), MoA (kisspeptin receptor antagonist, neurokinin 3 receptor antagonist, AMPK activator, and others ), geographical segmentation (US, Germany, and Belgium) and recruitment status (recruiting, active, not recruiting, and completed). It provides an in-depth analysis of the prominent factors influencing the market, including drivers, opportunities, trends, and industry-specific challenges.
Almost 89% of the molecules that are being investigated for the treatment of polycystic ovary syndrome are small molecule.
Looking for more information on this market? Request a free sample report
Technavio’s sample reports are free of charge and contain multiple sections of the report such as the market size and forecast, drivers, challenges, trends, and more.
Some of the key topics covered in the report include:
Scope of the Report
Regulatory Framework
Drug Development Landscape
- Drugs under development
- Indications coverage
Drug Development Strategies
- Therapies employed
- RoA
- Therapeutic modality
- Geographical coverage
Recruitment Strategies
- Recruitment status
- Gender
- Age
Key Companies
- Type of players
- Company overview
Discontinued or Dormant Molecules
About Technavio
Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.
With over 500 specialized analysts, Technavio’s report library consists of more than 10,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
If you are interested in more information, please contact our media team at media@technavio.com.
